Skip to content
Tablet Allopathic

Deucrava 6 mg tablet

Generic: Deucravacitinib

Company: Ziska Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength6 mg
PackStrip: 1000.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated August 30, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Deucravacitinib 6 mg tablets

Prices as listed on BestinMeds.

2 brands listed
Cravacin80.00 taka per tablet
Deucrava (this medicine)100.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Deucravacitinib guide

Indications

Deucravacitinib is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is not recommended for use in combination with other potent immunosuppressants.

Dosage and administration

Recommended Evaluations and Immunizations Prior to Treatment Initiation: Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with Deucravacitinib. If positive, start treatment for TB prior to Deucravacitinib. Recommended Dosage: The recommended dosage of Deucravacitinib is 6 mg taken orally once daily, with or without food. Do not crush, cut, or chew the tablets. Pediatric Use: The safety and effectiveness in pediatric patients have not been established. Geriatric Use: No overall differences in effectiveness have been observed between patients 65 years of age and older and younger adult patients. Recommended Dosage in Patients with Hepatic Impairment: Deucravacitinib is not recommended in patients with severe hepatic impairment (Child-Pugh C). No dosage adjustment is needed for patients with mild to moderate hepatic impairment. Renal Impairment: No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis.

Side effects

The most common side effect of Deucravacitinib include common cold, sore throat, and sinus infection (upper respiratory infections), cold sores (herpes simplex), sores on inner lips, gums, tongue, or roof of the mouth (canker sores), inflamed hair pores (folliculitis), acne. lt may cause serious allergic reactions including feeling faint or swelling in the face, eyelids, lips, mouth, tongue, or throat, trouble breathing or throat tightness or chest tightness or skin rash, hives etc.

Precautions and warnings

Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. Discontinue if a clinically significant hypersensitivity reaction occurs. Infections: Deucravacitinib may increase the risk of infection. Avoid use in patients with active or serious infection. If a serious infection develops, discontinue this until the infection resolves. Tuberculosis: Evaluate for TB prior to initiating treatment with Deucravacitinib. Malignancy: Malignancies including lymphomas were observed in clinical trials with Deucravacitinib. Laboratory Abnormalities: Periodically evaluate serum triglycerides. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease. Immunizations: Avoid use with live vaccines. Potential Risks Related to JAK Inhibition: It is not known whether TYK2 inhibition may be associated with the observed or potential adverse reactions of JAK inhibition. Higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with a JAK inhibitor compared to those treated with TNF blockers in rheumatoid arthritis (RA) patients. This is not approved for use in RA. Rhabdomyolysis and elevated CPK.

Pregnancy and lactation

Available data from case reports on Deucravacitinib use during pregnancy are insufficient to evaluate a drug-associated risk oi major birth defects, miscarriage. or adverse maternal or fetal outcomes. No effect on embryo-fetal development were seen in animal reproductive studies. There are no data on the presence of Deucravacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Deucravacitinib and any potential adverse effects on the breastfed infant from Deucravacitinib.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250